New therapies for the treatment of spastic cerebral palsy

Al Mosawi, AamirAamir Jalal Al Mosawi, is advisor doctor in pediatrics and pediatric psychiatry at the Children Teaching Hospital of Baghdad Medical City. He is also advisor doctor and expert trainer at the National Training and Development Center of the Iraqi Ministry of Health. He is the Head of Iraq Headquarter of Copernicus Scientists International Panel.

Cerebral palsy is a heterogeneous condition associated with a non-progressive lesion, but permanent disorder of movement with limited mobility. It is generally associated with gross motor developmental delay. In moderate to severe cases motor developmental milestones such as walking may never be achieved. There are no specific therapies for cerebral palsy, and treatment of spastic cerebral palsy is generally aiming at improving mobility through muscle relaxation and physiotherapy. This is a retrospective observational study describing the treatment of spastic cerebral palsy with individualized treatment plans providing a new combination of interventions including nutritional support, muscle relaxants and the use of oral pyritinol, intramuscular piracetam, citicoline (oral and injectable), intramuscular cerebrolysin, and intramuscular nandrolone decanoate. Treatment in this study aimed primarily at improving motor development particularly standing and walking. After treatment, all the patients experienced improvement in motor development without the occurrence of any side effect.